1. Home
  2. CDXS vs MSLE Comparison

CDXS vs MSLE Comparison

Compare CDXS & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$2.58

Market Cap

141.8M

Sector

Industrials

ML Signal

HOLD

MSLE

Satellos Bioscience Inc. Common Stock

N/A

Current Price

$8.63

Market Cap

146.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CDXS
MSLE
Founded
2002
N/A
Country
United States
Canada
Employees
N/A
17
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
141.8M
146.9M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
CDXS
MSLE
Price
$2.58
$8.63
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.4M
88.1K
Earning Date
05-13-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
43.82
N/A
EPS
N/A
N/A
Revenue
$138,590,000.00
N/A
Revenue This Year
$7.73
N/A
Revenue Next Year
$14.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
32.30
N/A
52 Week Low
$0.96
$5.50
52 Week High
$3.87
$13.39

Technical Indicators

Market Signals
Indicator
CDXS
MSLE
Relative Strength Index (RSI) 76.54 60.42
Support Level $2.37 $6.67
Resistance Level $2.86 $11.98
Average True Range (ATR) 0.18 0.72
MACD 0.06 0.45
Stochastic Oscillator 85.20 79.25

Price Performance

Historical Comparison
CDXS
MSLE

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

About MSLE Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Share on Social Networks: